OUR SERVICES

Cardiovascular & PulmonaryStem Cell Protocols

Regenerative Medicine Cardiovascular Disorders

The Role of Stem Cell Clinical Research
& Deployment




Post Myocardial Infarction (Post-MI) Congestive Heart Failure (CHF) Cardiomyopathy Chronic Obstructive Pulmonary Disease (COPD) Chronic Bronchitis Emphysema Asthma

Cardiovascular disorders includes all conditions involving the heart and vascular system (the arterial and venous blood vessels). The most common cardiovascular disorder is atherosclerotic coronary artery disease (ASCVD), which affects the arteries (especially the coronary arteries) and is the leading cause of heart attacks and death.

Other cardiovascular disorders may also involve the cardiac muscle, cardiac valves, heart rhythm, and peripheral blood vessels throughout the body. Many patients are typically treated with a multitude of medications; many patients require surgical interventions such as coronary angioplasty, coronary artery bypass, or other surgeries. Often patients, despite maximum therapy with medications and surgery, continue to suffer pain, discomfort, disability and have marked restrictions in their normal daily living activities.





Stem Cell Clinical Research & Deployment – Cardiovascular Problems

These ADSC’s cells are derived from fat – an exceptionally abundant source of stem cells – that has been removed during our mini-liposuction office procedure. The source of the regenerative stem cells actually comes from stromal vascular fraction (SVF) – a protein rich segment from processed adipose tissue. Stromal vascular fraction contains a mononuclear cell line (predominantly autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important growth factors that facilitate the stem cell process and promote their activity. Our technology allows us to isolate high numbers of viable cells that we can deploy during the same surgical setting.

They are then deployed back into the patient’s body via injection or IV infusion on an outpatient basis; the total procedure takes less than two hours. Not all cardiovascular problems respond to stem cell therapy, and each patient must be assessed individually to determine the potential for optimal results from this regenerative medicine process.

CLERO Stem Cell Center is committed not only to providing a high degree of quality care for our patients with cardiovascular problems – but we are also highly committed to clinical stem cell research and the advancement of regenerative medicine. At CLERO Stem Cell Center we exploit anti-inflammatory, immuno- modulatory and regenerative properties of adult stem cells to mitigate cardiac ischemia.





Post MI

Myocardial infarction (“heart attack”) is responsible for significant cardiac muscle destruction and impairment due to ischemia (lack of blood flow). This can lead to further or recurrent restriction of blood flow thereby causing re-current infarct and pain on exertion (or even rest) known as chronic angina. Chronic angina causes restriction of daily activities of everyday living and is plagued with chest pain, chest pressure, and depression. This problem is caused most commonly by coronary artery disease which is very common in the United States and associated with significant morbidity and mortality.

Cell therapy potentially offers an important adjunct in the solution for chronic ischemia and chronic angina. During cardiac ischemia, millions of myocytes (heart muscle cells) are damaged or lost, thereby resulting in loss of contractile (pumping) function. One of the great goals of regenerative medicine is to engineer methods of replacing these cells.

The results of numerous clinical trials of the use of adult mesenchymal stem cells to treat cardiac disease have demonstrated safety and most have shown positive clinical results. Mesenchymal stem cells have been deployed intravenously, injected into the myocardium, and placed in the coronary arteries and it is still unclear if one delivery method is clearly superior to another. Because adipose derived stem cells appear to be highly effective in this area, at CLERO’ s Stem Cell Treatment Center we continue to investigate the effects of SVF (rich in mesenchymal stem cells and growth factors) on damaged myocardium. We use a protocol designed by our interventional cardiologist that includes outpatient intravenous deployment without the need for cardiac catheterization.

In one recent scientific article (Regen Med. 2011 Nov;6 (6 Suppl): 17-23, Stem cell therapy in cardiology, by Choudry FA, Mathur A, conducted at the London Chest Hospital, London, UK) it is noted that cell therapy provides one of the “most important solutions to the unmet need for new treatments in cardiovascular disease.” The continued success of this area of translational and regenerative medicine relies on the ongoing partnership between clinicians and scientists, who have thus far demonstrated a determined and pragmatic approach to solving some of the complexities of transitioning between scientific investigational research protocols and clinical therapeutic modalities.





CHF and Cardiomyopathy

Congestive heart failure (CHF) is a disease of the heart muscle. When the heart muscle is weakened and damaged by heart attack, chronic hypertension, heart disease, cardiomyopathy, infection, or toxins– the heart becomes unable to pump enough blood to meet the body’s requirements. In its early stages of CHF there may be little if any signs, as the heart muscle compensates by enlarging and thickening so it can beat faster and more strongly. After some time of “compensating” – the heart muscle itself becomes fatigued and weak. This results in generalized fatigue, shortness of breath, edema (fluid retention) of the lower extremities, amongst an array of other symptoms and infirmities.

Congestive heart failure (CHF) is responsible for millions of hospitalizations in the U.S. and is considered the main cause or contributor to 53,000 deaths each year in the United States. CHF is often associated with cardiomyopathy (deterioration in heart muscles). Cardiomyopathy is commonly caused by coronary artery vessel disease but can also be due to infection and other causes. In CHF, the heart loses its ability to pump blood efficiently; the result is a weakened, and at times, almost flabby cardiac muscle.

Stem cell therapy potentially offers an important adjunct in the treatment solutions for CHF and cardiomyopathy. At Clero Stem Cell Treatment Center we exploit anti-inflammatory, immuno- modulatory and regenerative properties of adult stem cells to mitigate cardiac ischemia and the weakened cardiac musculature found in CHF.

At CLERO Stem Cell Center, we are committed not only to a high degree of quality care for our patients with heart failure but also to stem cell research and the advancement of regenerative medicine. Not all cases of heart failure respond to stem cell therapy, and each patient must be assessed individually to determine the potential for optimal results from this regenerative medicine process.

The Clero Stem Cell Treatment Center’s protocol for heart failure involves the potential benefits of adult stem cells. In an outpatient procedure performed by our experienced and skilled surgeon, a small amount of fat is removed during a mini-liposuction procedure. The patient’s fat–the richest source of stem cells–is then processed and the stem cells are separated out. These cells are then redeployed via an intravenous injection back into the patient – all on an outpatient basis. The entire regenerative medicine procedure takes less than two hours from start to finish.





Pulmonary Stem Cell Protocols

Regenerative Medicine for Pulmonary Disorders
- The Role of Stem Cell Clinical Research & Deployment -
Stem Cell Clinical Research & Deployment
– Pulmonary Disorders -

COPD

More than 10 million Americans suffer with chronic obstructive pulmonary disease (COPD). COPD includes a number of diseases such as: Emphysema and Chronic Bronchitis.

COPD is one of the most common lung diseases – pathologically it simply makes it difficult to breathe. The chronic bronchitis form of COPD involves a long-term cough with mucus production; the emphysema form of COPD involves destruction of the lung tissue over time. Most people with COPD have a combination of both conditions. It is a highly inflammatory condition. Smoking is the leading cause of COPD.

Typical treatments for COPD include steroids, bronchodilators and antibiotics; they are used recurrently in COPD patients because they recognized as the fourth- leading cause of death. COPD is considered a “progressive” lung disease in that, over time, the disease worsens and becomes more limiting.





The Clero Stem Cell Treatment Center offers protocols and investigational use of Autologous Adult Adipose Derived Stem Cells (ADSC’s) for clinical research and deployment for several pulmonary diseases: COPD / Emphysema / Chronic Bronchitis / Asthma.

These ADSC’s cells are derived from fat–an exceptionally abundant source of stem cells–that has been removed during our mini-liposuction office procedure – as an outpatient procedure. They are then deployed back into the patient’s body via injection or IV infusion on an outpatient basis; the total procedure takes less than two hours. Not all pulmonary problems respond to stem cell therapy, and each patient must be assessed individually to determine the potential for optimal results from this regenerative medicine process.

The CLERO Cell Treatment Center is committed not only to providing a high degree of quality care for our patients with pulmonary disease – but we are also highly committed to clinical stem cell research and the advancement of regenerative medicine. At the Clero Stem Cell Treatment Center we exploit the anti-inflammatory and regenerative properties of adult stem cells to mitigate the inflammatory and degenerative aspects of pulmonary diseases to control the loss of elasticity and damage in the small airways of patients with COPD.Clero Stem Cell Treatment Center investigates the effects of SVF (rich in mesenchymal stem cells and growth factors) on airway healing and we use protocol that includes a combination of intravenous and nebulized SVF delivery. The Stem Cell deployment protocol performed under local anesthesia is all done as an outpatient at the time of SVF harvesting, procurement and deployment. The entire stem cellular surgical procedure takes less than two hours.





Asthma

Asthma is a common chronic inflammatory disease of the airways characterized by symptoms including wheezing, coughing, chest tightness, and shortness of breath, reversible airflow obstruction, and bronchospasm. Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate. Asthma can also be either exercised induced or occupational. Asthma affects an estimated 300 million people worldwide and causes about 250,000 deaths per year.

In the United States, asthma affects approximately 26 million people – including almost 10 percent of our children. Asthma causes patients to experience wheezing, shortness of breath, and gasping for air. The incidence of Asthma is rapidly skyrocketing – over the last 25 years the incidence of asthma has more than doubled. Asthma is a highly inflammatory disease often requiring strong inhalers and corticosteroids to stop the inflammatory response.

At the Clero Stem Cell Treatment Center, we have a protocol for asthma that involves the patient’s own adult stem cells; our protocol includes a combination of intravenous and nebulized SVF delivery. The stem cells are isolated from a small amount of fat–the richest source of stem cells – which are obtained during a mini-liposuction procedure. The stem cells are harvested, concentrated and then deployed (re-infused) back into the patient’s body via intravenous infusion – all in an outpatient procedure.

The procedure takes less than two hours.

Contact Us

Address

Middle East
Bahrain

Zinj Manama

Doha | Qatar

Boston Medical Center Al Waab street Doha Qatar


USA
Beverly Hills Los Angeles California
Las Vegas Nevada

Dr. Pierre R. Clero MD.

US Number

+1 702 6054502

Bahrain
Faith Ocampo: Patient coordinator:

+973 36197919

DOHA | QATAR

+974 33861017